HSRProj will be retired on September 14, 2021, no updates will be made to HSRProj after this date.
Detailed information about this transition can be found on the June 3, 2021 Technical Bulletin post.
If you have questions or suggestions, please contact NLM Customer Service.
Information about ongoing health services research and public health projects
|Promoting informed decisions about lung cancer screening|
|Investigator (PI):||Volk, Robert|
|Performing Organization (PO):||
(Current): University of Texas, MD Anderson Cancer Center, Division of Internal Medicine, Department of General Internal Medicine / (713) 745-4516
|Supporting Agency (SA):||Patient-Centered Outcomes Research Institute (PCORI)|
|Record Source/Award ID:||PCORI/CER-1306-03385|
|Funding:||Total Award Amount: $1,913,609|
|Award Information:||PCORI: More information and project results (when completed)|
|Abstract:||For smokers, lung cancer is an ever-present fear. In 2013, about 160,000 people in the US will die from lung cancer. Smoking is the #1 risk factor for lung cancer, and quitting smoking is the best way to lower the risk. Smoking is also a risk factor for other cancers and health problems including heart and lung disease. We now have a secondary prevention strategy--annual screening with low-dose computed tomography (LDCT scans) that has the potential to greatly reduce lung cancer deaths. Current estimates are that over 12,000 lung cancer deaths would be prevented each year if heavy smokers 55 to 74 years of age were screened annually. But, there are risks associated with LDCT scans, including radiation exposure and a high likelihood of having a scan incorrectly suggest lung cancer is present. These false positives can lead to additional tests that may result in patients being harmed. Leading medical groups recommend LCDT scans for high-risk smokers, while encouraging patients to quit smoking. These groups further recommend that patients be given the opportunity to make a shared decision about lung cancer screening, considering what is important to them related to the potential benefits and harms of screening. Patient decisions aids are educational tools that help patients understand their options, including the benefits or harms of each option, weigh their values related to the benefits and harms, and make an informed decision often with a health care provider based on what is most important to them. We worked closely with smokers, cancer prevention clinicians, and tobacco control experts to develop a prototype video decision aid titled "Lung Cancer Screening Is it right for me?" This study will update the video decision aid to be consistent with current guidelines from medical groups. We will then test the decision aid in a randomized controlled trial where patients will receive either the decision aid video or standard educational materials from the National Cancer Institute that describe lung cancer screening but do not emphasize it as a decision where patients may decide for or against screening. For the study 400 patients of the Alabama and Mississippi tobacco quitlines will participate. They will complete surveys at 1 week and 3 months after receiving the video or standard educational materials to determine how prepared they were to make a screening decision and if they decided to be screened. We will work with a stakeholder advisory group, including primary care physicians, tobacco quitlines across the US, and members of national cancer control groups, to develop a plan to ensure the findings and the products of the study are made available on a broad scale. This project will provide patients with information they find important about lung cancer screening and the tradeoffs between the potential benefits and harms of being screened so they can be prepared to make shared decisions consistent with their personal values and preferences.|
|Record History:||('2017: Project extended to 2018.',)|